The role of glucagon-like peptide 1 (GLP-1) in addictive disorders
Research output: Contribution to journal › Review › Research › peer-review
Standard
The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. / Kruse Klausen, Mette; Thomsen, Morgane; Wortwein, Gitta; Fink-Jensen, Anders.
In: British Journal of Pharmacology, Vol. 179, No. 4, 2022, p. 625-641.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The role of glucagon-like peptide 1 (GLP-1) in addictive disorders
AU - Kruse Klausen, Mette
AU - Thomsen, Morgane
AU - Wortwein, Gitta
AU - Fink-Jensen, Anders
PY - 2022
Y1 - 2022
N2 - Drug, alcohol and tobacco use disorders are a global burden affecting millions of people. Despite decades of research, treatment options are sparse or missing, and relapse rates are high. Glucagon-like peptide 1 (GLP-1) is released in the small intestine, promotes blood glucose homeostasis, slows gastric emptying and reduces appetite. GLP-1 receptor agonists approved for treating Type 2 diabetes mellitus and obesity have received attention as a potential anti-addiction treatment. Studies in rodents and non-human primates have demonstrated a reduction in intake of alcohol and drugs of abuse, and clinical trials have been initiated to investigate whether the preclinical findings can be translated to patients. This review will give an overview of current findings and discuss the possible mechanisms of action. We suggest that effects of GLP-1 in alcohol and substance use disorders is mediated centrally, at least partly through dopamine signalling, but precise mechanisms are still to be uncovered.
AB - Drug, alcohol and tobacco use disorders are a global burden affecting millions of people. Despite decades of research, treatment options are sparse or missing, and relapse rates are high. Glucagon-like peptide 1 (GLP-1) is released in the small intestine, promotes blood glucose homeostasis, slows gastric emptying and reduces appetite. GLP-1 receptor agonists approved for treating Type 2 diabetes mellitus and obesity have received attention as a potential anti-addiction treatment. Studies in rodents and non-human primates have demonstrated a reduction in intake of alcohol and drugs of abuse, and clinical trials have been initiated to investigate whether the preclinical findings can be translated to patients. This review will give an overview of current findings and discuss the possible mechanisms of action. We suggest that effects of GLP-1 in alcohol and substance use disorders is mediated centrally, at least partly through dopamine signalling, but precise mechanisms are still to be uncovered.
KW - addiction
KW - alcohol
KW - alcohol use disorder
KW - amphetamine
KW - cocaine
KW - dopamine
KW - GLP-1
KW - glucagon-like peptide-1
KW - nicotine
KW - opioids
KW - substance use disorder
KW - tobacco
KW - WITHDRAWAL-INDUCED ANXIETY
KW - VENTRAL TEGMENTAL AREA
KW - NUCLEUS-ACCUMBENS
KW - RECEPTOR AGONISTS
KW - CONCISE GUIDE
KW - FOOD-INTAKE
KW - MESSENGER-RNAS
KW - ALCOHOL
KW - COCAINE
KW - EXENDIN-4
U2 - 10.1111/bph.15677
DO - 10.1111/bph.15677
M3 - Review
C2 - 34532853
VL - 179
SP - 625
EP - 641
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
SN - 0007-1188
IS - 4
ER -
ID: 291676532